TACE plus immune checkpoint inhibitor-based systemic therapies for hepatocellular carcinoma

被引：0
|
作者：
Reiter, Florian P. [1 ]
Geier, Andreas [1 ]
机构：
[1] Univ Hosp Wurzburg, Dept Med 2, Div Hepatol, D-97080 Wurzburg, Germany
来源：
LANCET | 2025年 / 405卷 / 10474期
关键词：
LOCOREGIONAL THERAPIES; END-POINTS; SURVIVAL;
D O I：
10.1016/S0140-6736(24)02680-1
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：174 / 176
页数：3
相关论文
共 50 条
  • [21] Conversion surgery for hepatocellular carcinoma in the new era of targeted and immune checkpoint inhibitor therapies
    Zhao, Lei
    Zhao, Haitao
    HEPATOBILIARY SURGERY AND NUTRITION, 2020, 9 (06) : 809 - 811
  • [22] Systemic Chemotherapy with Combination of Immune Checkpoint Inhibitor and Tyrosine Kinase Inhibitor in Unresectable Hepatocellular Carcinoma
    Chon, Hye Yeon
    KOREAN JOURNAL OF GASTROENTEROLOGY, 2024, 83 (02): : 78 - 80
  • [23] Effects of immune checkpoint inhibitor-based combination therapies on the gut microbiota in advanced melanoma patients
    Li, J.
    Xu, L.
    Peng, Z.
    Jiang, H.
    Chao, F.
    Ding, Y.
    Moll, J. M.
    Li, D.
    Wen, X.
    Wang, J.
    Ding, Q.
    Zhang, L.
    Kristiansen, K.
    Brix, S.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S934 - S934
  • [24] Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues
    Yang, Shiye
    Liang, Huoqi
    Li, Xing
    Qian, Jiayi
    Ming, Zhibing
    HEPATOLOGY INTERNATIONAL, 2024, 18 (04) : 1336 - 1337
  • [25] Meta-analysis of surrogate endpoints for survival in patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitor-based regimens
    Zhu, Andrew X.
    Lin, Yong
    Ferry, David Raymond
    Widau, Ryan C.
    Saha, Abhijoy
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [26] A phase II clinical trial to study the efficacy of cabozantinib in patients with hepatocellular carcinoma refractory to immune checkpoint inhibitor-based treatment
    Chan, S.
    Ryoo, B-Y.
    Mo, F.
    Cheon, J.
    Li, L.
    Wong, K. H.
    Nicole, Y.
    Kim, H.
    Yoo, C.
    ANNALS OF ONCOLOGY, 2022, 33 : S1454 - S1454
  • [27] Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
    Pan, Hongyu
    Ruan, Minghao
    Jin, Riming
    Zhang, Jin
    Li, Yao
    Wu, Dong
    Sun, Wen
    Wang, Ruoyu
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Di Federico, Alessandro
    Frega, Giorgio
    Palloni, Andrea
    Tavolari, Simona
    Brandi, Giovanni
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [29] Dermatological adverse events associated with immune checkpoint inhibitor-based combinations of anticancer therapies: a systematic review
    Salloum, Antoine
    Habre, Maya
    Chebl, Joanna Abi
    Chebl, Karen Abi
    Atallah, Carl
    Medawar, Georgio
    Kourie, Hampig R.
    IMMUNOTHERAPY, 2022, 14 (06) : 489 - 503
  • [30] Mathematical modelling of tumour-immune interactions in presence of checkpoint inhibitor-based therapies for the treatment of cancer
    Arora, Vaibhav
    Ali, Sk Meheraj
    Das Karmakar, Arka
    Sen, Pramita
    MATERIALS TODAY-PROCEEDINGS, 2022, 57 : 1477 - 1483
12345